Change of Date, Time and Location of ESMO Abstract Presentation
LONDON AND PHILADELPHIA – September 15, 2025 – Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, confirms it will announce its unaudited interim results for the six months ended June 30, 2025 (“HY25”), on September 30, 2025.
Christina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will also deliver a live presentation via Investor Meet Company at 14:00 BST on the day.
The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via: AVCT – AVACTA GROUP PLC | Investor Meet Company
Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until September 30 09:00 BST, or at any time during the live presentation.
The Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/.
ESMO Congress Update
The Company confirms that the date, time and location of the abstract being presented at the European Society for Medical Oncology (ESMO) Congress, taking place from October 17-21, 2025, has changed. The updated details are included below:
Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Session Title: Developmental Therapeutics
Session Date and Time: 19 October, 12.00-12.45
Location: Hall 25
Abstract Presentation Number: 964P
Speaker: William D. Tap